Fort Dodge Animal Health (Wyeth) launched the first USDA approved vaccine in 2006, containing an inactivated virus (ATCvet code: QI09AA07 (WHO)).

[2] Three strains of PCV are known as of 2018: PCV-1 and PCV-2 show a high degree of sequence identity and a similar genomic organisation; nevertheless, the basis of the distinct pathogenicity has not yet been unravelled.

[5] The termination of the replication sequence has not been identified, yet, though there is evidence supporting that Rep also represses its own promoter, Prep.

The promoter for this protein is located within ORF1, within the site where Rep' is truncated, and is splice from the same exon to the starting point of the ORF2 coding region[6] and expressed during both early and late phases.

Research has shown that PCV utilizes clathrin-mediated endocytosis to enter the cell, though it's speculated that there may still be other factors that haven't been identified.

Research has shown that the protein coded in ORF3 can modulate the host cell's cell-division cycle and cause cell-mediated, virus-induced apoptosis.

This increase in p53 stops the cell division cycle and the result of this is p53 mediated apoptosis, which releases PCV into the extracellular environment.

[12] On March 22, 2010, the U.S. Food and Drug Administration (FDA) recommended suspending the use of Rotarix, one of two vaccines licensed in the United States against rotavirus, due to findings of viral DNA contamination.

[13][14] As of June 8, 2010, the FDA has, based on a careful review of a variety of scientific information, determined it is appropriate for clinicians and public health professionals in the United States to use both Rotarix and RotaTeq vaccine.